Radioiodine therapy for papillary and follicular thyroid carcinoma.
Radioiodine ((131)I) therapy is used in patients with papillary and follicular thyroid carcinoma for ablation of thyroid remnants and for treatment of persistent or recurrent disease. It should be used selectively, i.e. only in those patients for whom a clinical benefit may be expected.
Department of Nuclear Medicine and Commissariat à l'Energie Atomique LRC 29V, Institut Gustave Roussy, 94805 Villejuif Cedex, France.
Michele
M
Klain
Marcel
M
Ricard
Sophie
S
Leboulleux
Eric
E
Baudin
Martin
M
Schlumberger
D018263:Adenocarcinoma, Follicular / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery; D000328:Adult; D002291:Carcinoma, Papillary / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D000075202:Contraindications; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007246:Infertility / Q000209:etiology; D007455:Iodine / Q000378:metabolism; D007457:Iodine Radioisotopes / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D007774:Lactation; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D018365:Neoplasm, Residual; D009381:Neoplasms, Radiation-Induced / Q000209:etiology; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic / Q000628:therapy; D011379:Prognosis; D019275:Radiopharmaceuticals / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011879:Radiotherapy Dosage; D018714:Radiotherapy, Adjuvant; D016019:Survival Analysis; D013964:Thyroid Neoplasms / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery; D013965:Thyroidectomy
D007457:Iodine Radioisotopes; D019275:Radiopharmaceuticals; D007455:Iodine